Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Guardian Therapeutics

Request full access

Guardian Therapeutics is a well-capitalized, privately owned drug discovery & development venture

Cambridge, United StatesFounded 2017Biotech & Life Sciences

About Guardian Therapeutics

Guardian Therapeutics was founded by James C. Gilbert and Shuhao Zhu, two visionaries in the field of biotechnology. With a shared passion for advancing medical science, they established the company with the goal of developing innovative therapeutics using nucleic acids that bind to specific target molecules. This approach aimed to address unmet medical needs and improve patient outcomes.

Under the leadership of Jim Gilbert, who brought nearly 30 years of industry experience from companies like Bayer and Boehringer Ingelheim, Guardian Therapeutics focused on drug discovery and development. The company quickly gained recognition for its cutting-edge research and development capabilities.

Despite being a privately owned venture, Guardian Therapeutics has been well-capitalized, allowing it to pursue its ambitious research agenda without the immediate pressures of public market demands. This financial stability has been crucial in enabling the company to focus on long-term goals and innovation.

While Guardian Therapeutics has not yet undergone an acquisition or IPO, its strategic focus and robust funding position it well for future growth opportunities. The company continues to explore potential partnerships and collaborations to expand its impact in the biotech industry.

Guardian Therapeutics stands as a testament to the power of scientific innovation and the dedication of its founders to improving healthcare through novel therapeutic solutions.

Source: Dealroom company data

At a glance

Status
Operational
Employees
95
Open positions
None listed
Dealroom signal
69.8/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Aug 2018 $20M $80M Undisclosed —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Guardian Therapeutics website traffic

Latest recorded traffic for Guardian Therapeutics is 43K monthly website visits, up 38.7% over the last three months. Guardian Therapeutics's team grew 5.6% over the past year.

Latest monthly visits43K 3-month web change+38.7% 1-year team growth+5.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Guardian Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Guardian Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 45 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Guardian Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Guardian Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.